Systemic cyclosporine A in severe atopic keratoconjunctivitis
Systemic cyclosporine A in severe atopic keratoconjunctivitis
复制标题
DOI：
10.1016/s0161-6420(97)30144-4
复制
发表时间：
1997-08-01
期刊：
影响因子：
13.7
通讯作者：
Robin, H
中科院分区：
文献类型：
--
作者：
HoangXuan, T;Prisant, O;Robin, H
目的：特应性角膜结膜炎（AKC）是一种潜在的致盲性疾病。它通常与特应性皮炎有关，在某些严重形式的疾病中，已成功地使用全身性环孢素A（CSA）进行治疗。在这项研究中，作者评价了严重AKC患者的全身CSA治疗。设计：队列。回顾性研究，参与者：4例年龄31 - 64岁的严重AKC和特应性皮炎患者，难治性或依赖于类固醇治疗，干预：患者接受口服CSA，主要结局指标：眼部炎症，皮肤状况，CSA治疗方法结果：口服CSA的日剂量为3 ~ 5 mg/kg，平均治疗时间为37个月（范围22-48个月）。3例患者眼部炎症完全控制。1例患者仅对治疗有部分反应。副作用包括肾毒性在一个病人，CSA剂量减少导致血清肌酐level.Conclusions正常化：这份报告表明，全身CSA是一个有趣的替代疗法，在严重的AKC。
Objective: Atopic keratoconjunctivitis (AKC) is a potentially blinding disease. It is usually associated with atopic dermatitis that has been managed successfully with systemic cyclosporine A (CSA) in some severe forms of the disease. in this study, the authors evaluated systemic CSA therapy in patients with severe AKC.Design: Cohort. Retrospective study,Participants: Four patients aged 31 to 64 with severe AKC and atopic dermatitis refractory to or dependent on steroid therapy,Intervention: The patients received oral CSA,Main Outcome Measures: Ocular inflammation, skin condition, CSA treatment methods (dosage, duration), CSA-related side effects.Results: Daily dosage of oral CSA was 3 to 5 mg/kg and mean duration of treatment was 37 months (range, 22-48 months). Ocular inflammation was controlled totally in three patients. One patient responded only partially to treatment. Side effects included renal toxicity in one patient, Reduction of CSA dosage resulted in normalization of serum creatinine level.Conclusions: This report suggests that systemic CSA represents an interesting alternative therapy in severe AKC.